Table 3.

Vaccination experiences of inactivated vaccines included in the expanded program of immunization in premature children

	Across three groups*	Delayed duration of time in the infants with a recommendation of normal vaccination (days), P50 (P25, P75)			Delayed duration of time in the infants with a recommendation of delayed vaccination (days), P50 (P25, P75)
	P value	Vaccinated before the assessment	Vaccinated after the assessment	P value **	Vaccinated before the assessment #	Vaccinated after the assessment	P value **
Hepatitis B vaccine (HepB)	-	49 (8, 93)	8 (2, 23)	<.001	-	-	-
Polio vaccine (PV)	-	0 (0, 44)	14 (0, 38)	<.001	-	-	-
Diphtheria tetanus pertussis vaccine (DTaP)	.097	0 (0, 29)	15 (0, 50)	<.001	-	247 (75, 362)	.001
Meningococcal serogroup A polysaccharide vaccine (MenA)	.086	0 (0, 50)	11 (0, 47)	.647	-	238 (33, 408)	.011
Japanese encephalitis vaccine (JEV)	.373	0 (0, 45)	0 (0, 65)	.617	-	154 (55, 237)	.003
Hepatitis A vaccine (HepA)***	-	0 (0, 151)	0 (0, 45)	.552	-	-	-

*The comparison was conducted between the recommendations of normal vaccination and delayed vaccination across three groups (vaccinated before the assessment, vaccinated after the assessment, and not ever vaccinated in this study) using Fisher’s exact test. For HepB, PV, and HepA, there was no recommendation of delayed vaccination.

**Mann-Whitney test was employed.

***Delayed duration of time in the vaccination of HepA was presented as P50 (P25, P90) due to limited sample size.

^#For HepB, PV, and HepA, there was no recommendation of delayed vaccination. For DTaP, MenA, and JEV, there was no vaccination before the assessment in children with a recommendation of delayed vaccination; thus, P value in the last column was compared between those vaccinated after the assessment with a recommendation of normal vaccination and those with a recommendation of delayed vaccination.